Studies gut and fat bacteria in people with rectal cancer
Looks at microbes in samples from patients with rectal cancer to predict outlook.
Plain-language title generated from the registry record
Registry title: Mesorectal Microbiome and Metabolome as a Prognostic Factor in Patients With Rectal Cancer
Key facts
- Where
- Girona, SpainSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults having planned (elective) surgery, either for colorectal cancer or for a non-cancer disease. The study looks at gut bacteria in the tissue around the rectum.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- Colorectal cancer with biopsy-proven adenocarcinoma or adenoma, tumour stage T1 or higher, and surgery planned to remove the whole tumour (R0 resection). People with a non-cancer disease needing planned surgery can also join.
- Earlier treatment
- Chemotherapy or neoadjuvant radiochemotherapy before surgery is allowed but not required. Cannot have had antibiotic, antifungal or antiviral treatment in the last 3 months, or long-term anti-inflammatory treatment.
Main reasons for not taking part
- Emergency surgery
- Another cancer at the same time
- Severe kidney or liver disease
- Inflammatory disease such as rheumatoid arthritis, Crohn's disease, asthma or chronic infection (HIV, TBC)
- Pregnancy or breastfeeding
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 18 years old?
Source: NCT04804956, who can take part
Where in Spain
- Hospital Universitari Dr. Josep Trueta de GironaGirona, SpainContact: Antoni Codina, MD, PhDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University Hospital of Girona Dr. Josep Trueta
- Trial code
- NCT04804956
- Record updated
- 10 June 2026
- Original description
The equilibrium of intestinal microorganisms is essential for health an imbalance has been associated with an increased risk in the development of different pathologies; including colorectal cancer.Read full original descriptionShow less
Mesorectal Microbiome and Metabolome as a Prognostic Factor in Patients With Rectal Cancer and Analysis of it's Applicability in Neoadjuvant Treatment
The equilibrium of intestinal microorganisms is essential for health an imbalance has been associated with an increased risk in the development of different pathologies; including colorectal cancer.
Rectal cancer is the third most common neoplasm worldwide and the complete excision of the mesorectum is a major prognostic factor.
The identification of microorganisms in the adipose tissue that surrounds the small intestine in inflammatory diseases, together with bacterial alterations found in colonic mucosa and feces in patients with rectal cancer in comparison with healthy individuals indicates that microbiome alteration plays an essential role in pathogenesis.
The mesorectal microbiome in rectal cancer patients stills unknown and given its importance in the prognostic of the disease the goal of this study is to identify microbial profiles that allow predicting rectal cancer patients with a poor prognosis.
Inclusion: Patients with colorectal cancer that will undergo elective surgery; Patients diagnosed with non-oncological disease with an indication for elective surgery; Age ≥ 18 years; Histology proven adenocarcinoma or adenoma with or without chemotherapy or neoadjuvant radiochemotherapy; Tumoral stage equal or grater than T1; Attempt to R0 resection; Signed informed consent by the patient and by the researcher; Dietary Questionnaire completed.
Exclusion: Emergency Surgery; Clinical symptoms and sings of infection in the previous month; Excessive alcohol intake or drug abuse; History of colorectal cancer surgery different to the local excision; Patients with psychiatric illness, addiction or disorder with inability to understand informed consent; Another synchronous malignancy; Severe kidney or liver disease; Systemic disease with inflammatory activity, such as rheumatoid arthritis, Crohn's disease, asthma, chronic infection (HIV,TBC); Severe disorder of eating behaviour; Major psychiatric antecedents; Colorectal tumor with different histology to adenocarcinoma or adenoma; Inability to read or understand any of the languages of the informed consent and questionnaires (Catalan, spanish); Any patient that medical characteristics present an individual risk raised to be included and complete the study; Pregnancy and lactation; Antibiotic, antifungal and antiviral treatment for the last 3 months; Anti-inflammatory chronic treatment.